Our top pick for
Avanos Medical Inc is a medical devices business based in the US. Avanos Medical shares (AVNS) are listed on the NYSE and all prices are listed in US Dollars. Avanos Medical employs 5,380 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$32.84|
|52-week range||$30.70 - $53.61|
|50-day moving average||$32.14|
|200-day moving average||$37.25|
|Wall St. target price||$43.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.04|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-08)||2.46%|
|1 month (2021-09-17)||-0.24%|
|3 months (2021-07-16)||-4.98%|
|6 months (2021-04-16)||-26.99%|
|1 year (2020-10-16)||-13.90%|
|2 years (2019-10-17)||-16.73%|
|3 years (2018-10-17)||62.01|
|5 years (2016-10-17)||34.03|
Valuing Avanos Medical stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Avanos Medical's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Avanos Medical's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 821x. In other words, Avanos Medical shares trade at around 821x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Avanos Medical's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $54.4 million.
The EBITDA is a measure of a Avanos Medical's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$737.8 million|
|Operating margin TTM||1.86%|
|Gross profit TTM||$390.6 million|
|Return on assets TTM||0.5%|
|Return on equity TTM||0.19%|
|Market capitalisation||$1.6 billion|
TTM: trailing 12 months
There are currently 1.2 million Avanos Medical shares held short by investors – that's known as Avanos Medical's "short interest". This figure is 18.6% up from 1.0 million last month.
There are a few different ways that this level of interest in shorting Avanos Medical shares can be evaluated.
Avanos Medical's "short interest ratio" (SIR) is the quantity of Avanos Medical shares currently shorted divided by the average quantity of Avanos Medical shares traded daily (recently around 380980.67484663). Avanos Medical's SIR currently stands at 3.26. In other words for every 100,000 Avanos Medical shares traded daily on the market, roughly 3260 shares are currently held short.
However Avanos Medical's short interest can also be evaluated against the total number of Avanos Medical shares, or, against the total number of tradable Avanos Medical shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Avanos Medical's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Avanos Medical shares in existence, roughly 30 shares are currently held short) or 0.026% of the tradable shares (for every 100,000 tradable Avanos Medical shares, roughly 26 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Avanos Medical.
Find out more about how you can short Avanos Medical stock.
We're not expecting Avanos Medical to pay a dividend over the next 12 months.
Over the last 12 months, Avanos Medical's shares have ranged in value from as little as $30.7 up to $53.61. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Avanos Medical's is 0.9026. This would suggest that Avanos Medical's shares are less volatile than average (for this exchange).
Avanos Medical, Inc. operates as a medical technology company that focuses on delivering medical device solutions to improve patients' quality of life in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions; and respiratory health products, such as closed airway suction systems and other airway management devices under the Ballard, Microcuff, and Endoclear brands. The company also provides a portfolio of non-opioid pain solutions, including acute pain products, such as On-Q and ambIT surgical pain pumps and Game Ready cold and compression therapy systems; and interventional pain solutions, which offers minimally invasive pain relieving therapies, such as Coolief pain relief therapy. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.